Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Phase 4

Completed

• Conditions: Overactive Bladder
• Interventions: Drug: mirabegron 50mg

• Registration Number: NCT02468375
• Lead Sponsor: Samsung Medical Center

Brief Summary

The purpose of this study is to measure the treatment satisfaction after switching to mirabegron in patient with Overactive Bladder(OAB) who were unsatisfied with efficacy of antimuscarinic therapy or adverse event.

Patient will take the mirabegron 50mg/day for 12 weeks, and the satisfation of the therapy will be measured with Treatment Satisfaction Questionnaire(TSQ), Global Response Assessment(GRA), OAB-q short form, OAB Symptom Score and Willingness to continue Questions.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2015-06
• Study Start: 2015-06
• Study First Submitted: 2015-06-07
• Study First Submitted QC: 2015-06-07
• Study First Posted: 2015-06-10
• Primary Completion: 2017-10
• Study Completion: 2017-12
• Last Update Submitted: 2018-02-26
• Last Update Posted: 2018-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 434

Inclusion Criteria

<SCREENING>

1. over 20 years old, who has overactive bladder at least for 3 months.
2. total OABSS score over 3 points, and number 3 question score should be over 2 points.
3. if one of the criteria met,

1. efficacy : who are unsatisfied with antimuscarinics during the past 2 years. (should be treated at least 8 weeks) 2) adverse event(AE) : who are unsatisfied with antimuscarinics treatment due to AE(dry mouth, constipation, etc) 4.subject who can write voiding diary. 5.subject who can understand about the study and sign the informed concent form.

<BASELINE> Voiding Diary for 3 days

1. micturition 8/day
2. urgency 2/day

Read More

Exclusion Criteria

<SCREENING>

1. subject has history or risk of acute urinary retension.

2. subject has prostate cancer.

3. subject has lower urinary tract obstruction and judge by investigator that the subject is not appropriate to participate in this study.

4. subject has a previous or current bladder tumor.

5. subject has significant stress incontinence or mixed incontinence where stress is the dominant factor.

6. prohibitied, permitted medication. 6-1. subject who has intake Alpha-blocker, Diabetes insipidus medication, PDE5 inhibitor(for BPH Tx), SSRI within 12weeks prior to Screening.

   6-2. subject who has started, stopped or changed the dose of 5-Alpha Reductase Inhibitors(5-ARI) within 4 weeks prior to Screening.

   6-3. Subject who currently intake Antimuscarinics, Antihistamines, Beta 2-adrenoreceptor agonist, loop diuretics,CYP2D6 substrates with narrow therapeutic index, CYP3A4 inducing agent, CYP 3A4 inhibitor, Antifungal agent, Antiarrythmic drugs.

7. subject who has Non-drug treatment including bladder training, pelvic floor muscle training within 12 weeks prior to Screening.

8. subject has severe hypertension which is defined as a sitting average systolic blood pressure over 180 mmHg, and/or diastolic blood pressure over 11 0mmHg.

9. pulse over 100 bpm or below 50 bpm.

10. subject has an indwelling catheter or practices intermittent self-catheterization.

11. subject who had surgery which can influence urinary track function (ex, TURP, Laser treatment,etc.).

12. subject who had complication of urinary tract infection, urinary stone, interstitial cystitis, or recurrent UTI history.

13. subject has known or suspected hypersensitivity to Beta 3 adrenalin receptor agonist.

14. subject has clinically significant cardiovascular diseases hepatic diseases renal diseases immunization diseases lung diseases and cancer.

15. subject who has planed pregnency, breast feeding during clinical trial period.

<BASELINE> voiding volume over 3000ml per day. post voiding residual volume over 200ml

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
mirabegron 50mg	mirabegron 50mg	about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Treatment Satisfation Questionnaire	at the end of the treatment( 12weeks)

Secondary Outcome Measures

Name	Time	Method
urgency change	4weeks, 12weeks
OABq-SF score change	4weeks, 12weeks
micturtion change	4weeks, 12weeks
incontinence change	4weeks. 12weeks
Willingness to continue Questions	12 weeks
OABSS score change	4weeks, 12weeks
Global Response Assessment(GRA) score change	4weeks, 12weeks

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul,, Korea, Republic of